Side-by-side comparison of AI visibility scores, market position, and capabilities
London and New York AI platform automating insurance prior authorization; reads patient clinical records to extract evidence justifying medical necessity and cut treatment delays.
Anterior is a London and New York-based healthtech company that applies AI to automate the prior authorization process, one of the most burdensome administrative tasks in U.S. healthcare. Prior authorization requires physicians to submit clinical evidence to insurance companies justifying the medical necessity of treatments, procedures, or medications — a process that consumes significant physician and staff time and causes treatment delays that harm patient outcomes. Anterior's AI reads patient clinical records, identifies the relevant clinical criteria required by the insurer, extracts supporting evidence from the patient's history, and generates complete prior auth submissions automatically. The platform also predicts approval likelihood and flags cases likely to require clinical review, helping health system staff prioritize their work. Founded in 2022, Anterior raised funding from investors including Sequoia Capital and has rapidly signed health system customers facing acute prior authorization burdens. The company's approach addresses a systemically inefficient process that costs the U.S. healthcare system an estimated $35B annually in administrative waste.
Thermo Fisher (TMO) reported $42.9B revenue in FY2024, down 1% YoY. World's #1 life sciences company. Serves pharma, biotech, labs globally. ~100,000 employees. HQ: Waltham, MA.
Thermo Fisher Scientific Inc. is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services to researchers, healthcare organizations, and industrial companies. Headquartered in Waltham, Massachusetts, Thermo Fisher was formed through the 2006 merger of Thermo Electron and Fisher Scientific and has since grown aggressively through acquisitions. The company reported revenues of $42.9B in FY2024, slightly down year-over-year after exceptional COVID-related revenue in 2021–2022.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.